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Introduction: Adjuvant platinum-based chemotherapy is
standard treatment for surgically resected stage II to IIIA
NSCLC, but the relapse rate is high. The preferentially
expressed antigen of melanoma (PRAME) tumor antigen is
expressed in two-thirds of NSCLC and offers an attractive
target for antigen-speciﬁc immunization. A phase I dose
escalation study assessed the safety and immunogenicity of
a PRAME immunotherapeutic consisting of recombinant
PRAME plus proprietary immunostimulant AS15 in patients
with surgically resected NSCLC (NCT01159964).
Methods: Patients with PRAME-positive resected stage IB to
IIIA NSCLC were enrolled in three consecutive cohorts to
receive up to 13 injections of PRAME immunotherapeutic
(recombinant PRAME protein dose of 20 mg, 100 mg, or 500
mg, with a ﬁxed dose of AS15). Adverse events, predeﬁned
dose-limiting toxicity, and the anti-PRAME humoral response
(measured by enzyme-linked immunosorbent assay) wereJournal of Thoracic Oncology Vol. 11 No. 12: 2208-2217
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assessed.
Results: A total of 60 patients were treated (18 received 20
mg of PRAME, 18 received 100 mg of PRAME, and 24 received
500 mg of PRAME). No dose-limiting toxicity was reported.
Adverse events considered by the investigator to be causally
related to treatment were grade 1 or 2, and most were in-
jection site reactions or fever. All patients had detect-
able anti-PRAME antibodies after four immunizations. The
percentages of patients with PRAME-speciﬁc CD4-positive T
cells were higher at the dose of 500 mg compared with lower
doses. No predeﬁned CD8-positive T-cell responses were
detected.
Conclusion: The PRAME immunotherapeutic had an
acceptable safety proﬁle. All patients had anti-PRAME hu-
moral responses that were not dose related, and 80% of
those treated at the highest dose showed a cellular immune
response. The dose of 500 mg was selected. However,
further development was stopped after negative results
with a similar immunotherapeutic in patients with NSCLC.
 2016 International Association for the Study of Lung
Cancer. Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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PRAME antigen; SafetyIntroduction
Lung cancer is the leading cause of cancer deaths
worldwide, with most cases being of the NSCLC histolog-
ical tumor type.1 Complete surgical resection of early-
stage NSCLC offers the best chance of cure, but the
5-year relative survival rates are 58.2% and 29.8% for
patients with localized and regional disease, respectively.2
Adjuvant platinum-based chemotherapy is now a standard
treatment option for surgically resected stage II to IIIA
disease.3,4 The moderate beneﬁts of adjuvant chemo-
therapy in NSCLC suggest that alternative strategies to
improve the outcome of these patients are needed.5–8
Cancer immunotherapy strategies aim to induce or
boost immune-mediated tumor cell destruction (active
immunotherapy) or to counteract the mechanisms by
which tumor cells evade or suppress immune-mediated
destruction (passive immunotherapy).9–13 Several strate-
gies, including immune-checkpoint inhibitors14–16 and
active immunotherapies,17–22 have entered late-stage
clinical development. Immune checkpoint inhibitors
include the anti–cytotoxic T-lymphocyte associated protein
4, anti–programmed cell death 1, and anti–programmed
death ligand 1 compounds that target tumor-mediated in-
hibition of cytotoxic T-cell activity. Preliminary evidencesuggests promising activitywithmanageable toxicitywhen
these compounds are administered as monotherapies or in
combination with chemotherapy or targeted agents.23,24
Currently, there are no immunotherapeutic agents
approved for use as adjuvant therapy for surgically resec-
ted NSCLC.3 The human tumor antigen preferentially
expressed antigen of melanoma (PRAME) was originally
identiﬁed by using a cytolytic T-lymphocyte clone derived
from a patient with melanoma, and its messenger RNA is
expressed in low levels in normal ovary, endometrium,
kidney, and adrenal medulla.25,26 PRAME has been identi-
ﬁed as a BC-box subunit of cullin 2–based E3 ubiquitin
ligase with interactions with nuclear transcription factor
Y.27,28 Functionally, PRAME may be associated with sup-
pression of retinoic acid receptor signaling and cell death
regulation,29 and it may be directly involved in oncogen-
esis.29,30 Expression of PRAME has been documented in a
variety of cancers, including NSCLC (adenocarcinoma
[46%] and squamous cell carcinoma [78%]),25 metastatic
melanoma (95%),25 breast carcinomas (27%),25,31 and
neuroblastoma (>90%).32 For some solid tumors such as
neuroblastoma and breast cancer, PRAME expression has
been linked to an unfavorable prognosis.32–35
We investigated the safety and immunogenicity of
escalating doses of a recombinant PRAME protein
(recPRAME, GSK, Rixensart, Belgium) administered with a
ﬁxed dose of the proprietary immunostimulant AS15
(referred to as the PRAME immunotherapeutic) in patients
with PRAME-positive pathological stage IB to IIIA NSCLC
after complete surgical resection. Here we report safety
and immunogenicity data measured 3 weeks after the
fourth administration of the PRAME immunotherapeutic
that led to dose selection according to predeﬁned rules.
Methods
The open-label, phase I study was conducted in 22
centers in Germany, France, Italy, Poland, the Russian
Federation, and the United States (ClinicalTrials.gov
identiﬁer NCT01159964). The study protocol was
approved by institutional review boards at each
participating center. Written informed consent was ob-
tained from each patient before the performance of any
study-speciﬁc procedures.
Coprimary objectives were to document and charac-
terize for each dose of the PRAME immunotherapeutic
tested the potential dose-limiting toxicities (DLTs) and the
anti-PRAME humoral immune response. Secondary objec-
tives included evaluation of the overall safety proﬁle and
cell-mediated antigen-speciﬁc immune (CMI) responses.Patients
Patients were 18 years of age or older with patholog-
ical stage IB to IIIA NSCLC after complete (R0) surgical
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Patients were allowed to receive adjuvant platinum-based
chemotherapy before enrollment. The tumor had to be
PRAME-positive as determined on the basis of formalin-
ﬁxed parafﬁn-embedded tissue samples by quantitative
reverse-transcriptase polymerase chain reaction at a
central laboratory (Response Genetics, Inc., Los Angeles,
CA).36 Protocol-deﬁned inclusion and exclusion criteria
are provided in the Supplementary Methods.Treatment Regimen
The composition of the PRAME immunotherapeutic
(recPRAME plus AS15) is provided in the Supplementary
Methods. The PRAME immunotherapeutic was adminis-
tered intramuscularly into the deltoid muscle or thigh,
alternating sides for each dose.
Escalating doses of recPRAME (20 mg, 100 mg, and
500 mg) combined with a ﬁxed dose of AS15 were
evaluated in three consecutive cohorts. A maximum of
13 injections of the PRAME immunotherapeutic were to
be administered according to the following schedule: the
ﬁrst ﬁve injections were given at 3-week intervals fol-
lowed by eight injections at 12-week intervals. Patients
were actively followed for an additional year for safety
and clinical outcomes. This regimen has been used for
the investigation of other immunotherapeutics, including
the melanoma-associated antigen A3 (MAGE-A3) immu-
notherapeutic in patients with NSCLC.37
Escalation to each dose level occurred when all 15
planned patients had initiated treatment with the lower
dose and when at least three patients had received at
least four injections. Dose escalation procedures are
provided in the Supplementary Methods.Assessment of Safety
All adverse events (AEs) occurring throughout the
study until 30 days after the last administration of the
study product were recorded. Serious adverse events
(SAEs) related to study treatment, DLTs, onset of auto-
immune disease, and pregnancy outcomes were recorded
for 1 year after administration of the last study treatment.
Disease recurrences and deaths due to disease were not
considered SAEs. AE severity was graded according to the
Common Terminology Criteria for Adverse Events,
version 4.0.38 AEs were coded to the preferred term level
using the Medical Dictionary for Regulatory Activities.39
A DLT was deﬁned as any of the following AEs
considered related or possibly related to administration
of the PRAME immunotherapeutic: (1) a grade 3 or
higher AE (myalgia, arthralgia, headache, fever, rigors/
chills, or fatigue persisting had to have persisted for 48
hours despite therapy to be considered a DLT), (2) a
grade 2 or higher allergic reaction occurring within 24hours after injection of PRAME immunotherapeutic, (3)
any decrease in renal function with a creatinine clear-
ance less than 40 mL/min, and (4) any symptomatic and
conﬁrmed adrenal insufﬁciency. Renal and adrenal AEs
were included because PRAME is expressed at low levels
in normal kidney and adrenal tissues.
At each visit, blood and urine samples were collected
for evaluation of a variety of routine hematologic,
biochemical, and coagulation parameters. Of note, mea-
surement of serum cortisol level and renal function tests
and urinalysis were performed at each visit, and an anti-
nuclear antibody test was performed at every second visit.
A data and safety monitoring committee and internal
safety review team reviewed the safety data, the clinical
relevance of any DLT event, and its relationship to the
study treatment.Immunogenicity
Humoral Immunity. Anti-PRAME antibody concentra-
tions were measured before administration of the ﬁrst
dose, 3 weeks after dose 2, and 3 weeks after dose 4.
Anti-PRAME immunoglobulin G (IgG) antibodies
were measured by enzyme-linked immunosorbent assay
as described in the Supplementary Methods. A humoral
immune response was deﬁned as a postimmunization
anti-PRAME antibody concentration equal to or above
the clinical cutoff value (12 EU/mL, deﬁned from 102
healthy donors) in initially seronegative patients (sero-
conversion) and a twofold or greater increase in post-
immunization anti-PRAME antibody concentrations in
initially seropositive patients.Cell-Mediated Immunity. CMI response was measured
before the ﬁrst dose and 3 weeks after dose 4, as
described in the Supplementary Methods. Brieﬂy, the
presence and functionality of the PRAME-reactive T-cell
response was assessed by stimulation of peripheral blood
mononuclear cells in an in vitro multiple-well assay.
PRAME T-cell immunogenicity (characterized by
detection and quantiﬁcation of T cells producing both
interferon-g [IFN-g] and tumor necrosis factor-a [TNF-a]
in an in vitro assay) cutoff scores for a positive response
were deﬁned from a panel of healthy donors (n ¼ 23,
cutoff of 2.68 for CD4-positive T-cell analysis and 1.15 for
CD8-positive T-cell analysis). A patient was considered a
CD4-positive or CD8-positive T-cell responder if the ratio
of immunogenicity scores between a positive post-
immunization sample and its corresponding baseline was
4 or greater. Frequencies of PRAME-speciﬁc T cells were
estimated on the basis of quantiﬁcation of deﬁned posi-
tive wells in the in vitro assay. Frequency cutoffs were
deﬁned from healthy donors as 6.32  10-6 for CD4
positivity and 1.9  10-6 for CD8 positivity.
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The dose was selected on the basis of safety and
immunogenicity data. A speciﬁc dose was considered
adequate if no more than two cases of DLT were re-
ported at any time among the 15 patients in each cohort
and if the dose showed anti-PRAME antibody responses
of 70% or more (11 of 15 patients) after four immu-
nizations. If more than one dose level satisﬁed both the
safety and humoral immune response criteria, selection
of the dose would also take into account CMI responses.
If the best immunological dose could not be deter-
mined by applying these criteria, the highest dose
with acceptable safety and immunogenicity was to be
selected.
Statistical Analysis
All statistical analyses were performed using SAS
software version 9.2 (SAS, Inc., Cary, NC). The study was
descriptive and no comparative tests were performed.
The total treated cohort included all patients enrolled
into the study who had received at least one injection of
PRAME immunotherapeutic. The according-to-protocolFigure 1. Patient ﬂow through the study until 3 weeks after
received by the laboratory. Inconclusive means invalid test resu
who completed the study until 3 weeks after the fourth immu
PRAME, preferentially expressed antigen of melanoma; SAE, secohort for immunogenicity included all patients who
met the eligibility criteria, complied with the protocol-
deﬁned procedures, had received at least the ﬁrst four
PRAME immunotherapeutic doses, and had completed
the study visit 3 weeks after the fourth immunization.
Geometric mean antibody concentrations were calcu-
lated for anti-PRAME IgG antibodies.
Results
From July 12, 2010, to October 17, 2011, 357 patients
were screened. Of the 342 patients with a valid test
result, 198 (57.9%) had a PRAME-positive tumor and 60
were enrolled into the study (Fig. 1). The data lock point
(DLP) for dose selection was on 28 February 2012. The
overall mean age of patients in the total treated popu-
lation was 62.8 years. Squamous cell carcinoma and
adenocarcinoma were the most frequent histological
tumor types in each cohort (Table 1). Approximately
40% of patients in each cohort had received prior
platinum-based adjuvant chemotherapy.
At the time of the DLP, 365 doses of PRAME
immunotherapeutic were administered across the threethe fourth immunization. Missing means no tumor sample
lt or quantity not sufﬁcient for testing. Numbers of patients
nization: 15 in cohort 1, 17 in cohort 2, and 22 in cohort 3.
rious adverse event; AE, adverse event.
Table 1. Demographic and Disease Characteristics (Total Treated Cohort)
Characteristics
Cohort 1 (20 mg)
n ¼ 18
Cohort 2 (100 mg)
n ¼ 18
Cohort 3 (500 mg)
n ¼ 24
Age at screening, y
Mean ± SD 61.3 ± 7.55 62.3 ± 8.12 64.1 ± 8.16
Median 61.0 62.0 64.5
Range 46–71 50–76 48–78
Sex
Female 4 2 10
Male 14 16 14
ECOG PS
0 13 11 13
1 5 7 11
T category
T1A 0 1 1
T1B 0 1 1
T2A 8 11 12
T2B 2 2 6
T3 8 3 4
N category
N0 12 8 16
N1 5 7 7
N2 1 3 1
Stage
IB 7 6 10
IIA 1 7 7
IIB 7 0 4
IIIA 3 5 3
Histopathological type
Adenocarcinoma 5 5 10
Adenocarcinoma, bronchioloalveolar 2 0 0
Adenosquamous carcinoma 1 0 1
Large cell carcinoma 1 1 1
Squamous cell carcinoma 8 11 12
Other 1 1 0
Platinum-based adjuvant chemotherapy
Yes (no) 8 (10) 7 (11) 9 (15)
ECOG PS, Eastern Cooperative Oncology Group performance status.
2212 Pujol et al Journal of Thoracic Oncology Vol. 11 No. 12cohorts, all patients had received at least one dose, 45 of
60 patients continued to receive treatment, and the
highest number of doses administered to any patient
was 10.
After the DLP, issues impacting the electronic data
capture system used in this study (the e-N@ble Web
system) were detected between April and May 2013. The
issues related to incorrect signatory display and the
audit trail. There was no impact on data integrity or on
the analyzed data. The technical root cause was identi-
ﬁed and corrective actions were taken. There was no
impact on subject safety. Submission of this paper was
delayed until all issues were fully resolved.
Safety
DLT and Study Withdrawals. No case of DLT was
reported.
Five patients were withdrawn from study treatment
before the ﬁfth immunization (see Fig. 1), including threewho were withdrawn for safety reasons. One patient in
cohort 1 was withdrawn on account of a related SAE. In
this 69-year-old male with underlying myopericarditis
after pneumonectomy, hypertension, atrial ﬁbrillation,
and dyspnea, acute pulmonary edema (grade 2) devel-
oped on the day after dose 2 and 7 days after reduction
of the furosemide dose and lasted for 1 day. Two pa-
tients in cohort 3 were withdrawn: one owing to an SAE
(transitional cell carcinoma considered unrelated to
treatment) and one because of a nonserious AE.
AEs. Between dose 1 and the DLP, at least one AE
(related or unrelated) was reported by 78% of patients
(14 of 18) in cohort 1, by 83% (15 of 18) in cohort 2, and
by 100% (24 of 24) in cohort 3. All but three of the
reported AEs were grade 1 or grade 2. There were 46
patients (12 each in cohorts 1 and 2 and 22 in cohort 3)
who reported treatment-related AEs, all of which were
grade 1 or 2 (Table 2). The most frequently reported
Table 2. Summary of Treatment-Related Adverse Events Reported at Least Twice in Any Group (Any Grade) from Dose 1 until
the Data Lock Point, by Maximum Grade (Total Treated Cohort)
Adverse Event
Cohort 1
n ¼ 18a
Cohort 2
n ¼ 18a
Cohort 3
n ¼ 24a
Grade 1 Grade 2 Grade 1 Grade 2 Grade 1 Grade 2
nb nb nb nb nb nb
Injection site reaction 4 5 8 3 13 6
Pyrexia 4 3 6 2 7 1
Fatigue 1 — 2 1 4 1
Chills 2 1 3 — 1 1
Asthenia 1 — 2 — — 3
Headache — — 3 — 2 —
Arthralgia — 1 1 — 2 —
Inﬂuenza-like illness — 1 — — 2 —
Myalgia — — — — 3 —
Pain in extremity — — — — 2 —
Note: See Supplementary Table 1 for all treatment-related adverse events from dose 1 until the data lock point, by maximum grade (total treated cohort).
aNo. patients with at least one administered dose.
bNo. patients reporting the adverse event at least once.
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pain, erythema, and edema. Other frequent related
AEs included pyrexia, fatigue, chills, and asthenia. No
potential immune-mediated disease was reported.
Two deaths occurred during the study, both on ac-
count of progression of NSCLC. One of these patients
died while still undergoing the study treatment, whereas
the other died after having been withdrawn from the
study treatment because of disease recurrence. Five
SAEs were reported, including one (acute pulmonary
edema) that was considered possibly related to the
treatment and led to withdrawal of the patient from the
study (see earlier and Supplementary Table 1).
Abnormal Laboratory Test Results. There were three
cases of grade 3 abnormal laboratory parameters, none
of which were reported as AEs: hyponatremia (an in-
crease from a sodium level of 131 mmol/L at screening
to 127 mmol/L at the time of the sixth immunization
[ongoing at the DLP] but no hyperkalemia) developed in
one patient (in cohort 2), and two patients (in cohort 3)
had increased g-glutamyl transferase levels present at
screening that remained unchanged during the study.
The abnormal laboratory test results reported as AEs
were one case of grade 1 decreased creatinine clearance
(in cohort 2) that developed 21 days after dose 2,
resolved after 35 days, and was considered unrelated to
treatment; one case of grade 1 decreased blood cortisol
level (in cohort 3) that developed on the day of dose 3,
was considered unrelated to treatment, and resolved
after 11 days; and one case of grade 1 increased creat-
inine clearance (in cohort 3) that developed on the day
of dose 2, was considered treatment related, and had an
unknown duration.Immunogenicity
Two patients (one in cohort 1 and one in cohort 2)
were seropositive for anti-PRAME IgG antibodies at
baseline. Neither had received prior chemotherapy. All
patients, except one in cohort 1 and two in cohort 3
(two of these patients had not received prior chemo-
therapy), were seropositive after two doses, and all
were seropositive and had a humoral response (see
“Methods”) at the post–dose 4 assessment (Fig. 2).
Anti-PRAME antibodies were higher after dose 4
than after dose 2 in all cohorts. Seropositivity rates
and geometric mean antibody concentrations after
four immunizations were similar in patients who
had or had not received prior platinum-based
chemotherapy (Fig. 2).
After four doses, the numbers of patients with
PRAME-speciﬁc CD4-positive T cells (TNF-a–positive/
IFN-g–positive) immunogenicity scores equal to or
above the cutoff were ﬁve of 10 in cohort 1, seven of 10
in cohort 2, and 14 of 15 in cohort 3 (Table 3). There was
a tendency toward a better induction of anti-PRAME
CD4þ T cells with increasing recPRAME dose, with the
highest estimated frequencies of PRAME-speciﬁc CD4-
positive cells observed in cohort 3. Similar immunoge-
nicity scores among individuals who had or had not
received prior chemotherapy were observed (Fig. 3).
Taking baseline immunogenicity scores into account,
after four immunizations the percentages of patients
with a PRAME-speciﬁc CD4-positive T-cell response
were 33% in cohort 1, 60% in cohort 2, and 80% in
cohort 3 (see Table 3).
After four doses, the numbers of patients with
PRAME-speciﬁc CD8-positive T cells (TNF-a–pos-
itive/IFN-g–positive) immunogenicity scores equal to or
Figure 2. Seropositivity rates and geometric mean antibody
concentrations (GMCs) for preferentially expressed antigen
of melanoma (PRAME) immunoglobulin G (IgG) antibodies
(according-to-protocol cohort for immunogenicity). N is
number of patients with available results, n/% is number/
percentage of patients with concentrations above the cutoff,
vertical lines indicate 95% conﬁdence intervals, dotted line
shows assay cutoff (12 EU/mL). Abbreviations: Pre, before
dose 1; Post II, 3 weeks after the second dose; Post IV, 3
weeks after the fourth dose; Post IV CT, patients who had
received platinum-based chemotherapy before study
enrollment; Post IV no CT, patients who had not received
prior chemotherapy.
2214 Pujol et al Journal of Thoracic Oncology Vol. 11 No. 12above the cutoff were one of 14 in cohort 1, zero of 13 in
cohort 2, and one of 14 in cohort 3. No CD8-positive
T-cell responder could be identiﬁed (see Table 3).
Dose Selection
All doses fulﬁlled the predeﬁned criteria for dose
selection in terms of safety and humoral immunoge-
nicity. There was a tendency toward better induction ofTable 3. PRAME-Speciﬁc CD4-Positive and CD8-Positive T Cells
Cellular Response, and Frequency before Treatment and after
Immunogenicity Scorea
(Cutoff)
Respo
Baseline
n/N (%)
After Dose 4
n/N (%)
(Cut
n/N (%
CD4 cells TNF-a (þ), IFN-g (þ) (cutoff ¼ 2.68)
Cohort 1 0 of 11 (0%) 5 of 10 (50%) 3 of 9
Cohort 2 2 of 11 (18%) 7 of 10 (70%) 6 of 10
Cohort 3 5 of 16 (31%) 14 of 15 (93%) 12 of 1
CD8 cells TNF-a (þ), IFN-g (þ) (cutoff ¼ 1.15)
Cohort 1 2 of 11 (18%) 1 of 9 (11%) 0 of 8
Cohort 2 0 of 11 (0%) 0 of 10 (0%) 0 of 10
Cohort 3 1 of 16 (6%) 1 of 13 (8%) 0 of 13
Note: See the Supplementary Data for details of the methods of assessment of c
protocol cohort at each visit (for response rates, N is the number of patients w
responders (column 4) or number with immunogenicity score (column 5) or freq
aSee Supplementary Data for deﬁnition of immunogenicity score.
bResponse rate means that the ratio of immunogenicity scores positive postimm
cFrequencies of PRAME-speciﬁc Tcells were estimated on the basis of quantiﬁcat
positive cells and 1.9  10-6 for CD8-positive cells).
PRAME, preferentially expressed antigen of melanoma; TNF-a, tumor necrosis fanti-PRAME CD4þ T cells with increasing antigen dose
without a major increase in AE frequency. Thus, as
deﬁned per protocol, the dose of 500 mg was selected for
further investigation.
Discussion
This phase I study was designed to select a recPRAME
dose for further development on the basis of safety and
immunogenicity criteria. We observed no cases of DLT, and
the safety proﬁle was consistent with that in a parallel study
of the PRAME immunotherapeutic in patients with
melanoma.40
In all patients, the PRAME immunotherapeutic
induced a humoral response that appeared to be inde-
pendent of the dose level. Pretreatment anti-PRAME
antibodies were observed in only two patients,
although our sample size of 60 patients was too small to
provide deﬁnitive estimates of baseline anti-PRAME
antibody production in patients with resected PRAME-
positive NSCLC tumors. Spontaneous humoral immune
responses against PRAME have not been described.41 As
in our experience with the PRAME immunotherapeutic,
few patients with NSCLC and melanoma expressing
MAGE-A3 had baseline anti–MAGE-A3 antibodies.42,43
By contrast, baseline antibodies to other tumor anti-
gens such as NY-ESO-1 are more frequently detected
(up to 23% for NY-ESO-1 baseline antibodies in
NSCLC44). The ability of some patients to mount an
immune response to tumor antigens may reﬂect dif-
ferences in tumor biology, individual immune compe-
tence, and previous or ongoing natural responses
against the tumor.(TNF-a–Positive/IFN-g–Positive) Immunogenicity Score,
Dose 4 (According-to-Protocol Cohort)
nse Rates to PRAMEb
Frequency above the Cutoffc
off and 4 Baseline)
)
Baseline
n/N (%)
After Dose 4
n/N (%)
(33%) 0 of 11 (0%) 6 of 10 (60%)
(60%) 1 of 11 (9%) 7 of 10 (70%)
5 (80%) 2 of 16 (13%) 14 of 15 (93%)
(0%) 0 of 11 (0%) 0 of 9 (0%)
(0%) 0 of 11 (0%) 0 of 10 (0%)
(0%) 0 of 16 (0%) 1 of 13 (8%)
ell-mediated immunity responses. N is number of patients in the according-to-
ith preimmunization and postimmunization results), and n is the number of
uency (column 6) above the deﬁned cutoff.
unization sample over baseline) is 4 or greater.
ion of deﬁned positive wells in the in vitro assay (cutoff ¼ 6.32  10-6 for CD4-
actor-a; IFN-g, interferon-g.
Figure 3. Preferentially expressed antigen of melanoma
(PRAME)-speciﬁc CD-positive T-cell (tumor necrosis factor-a–
positive/interferon-g–positive) immunogenicity scores
before treatment and after dose 4 (according-to-protocol
cohort for immunogenicity). Vertical lines indicate 95% con-
ﬁdence intervals, dotted line shows cutoff (2.68). See
Supplementary Data for details of the derivation of cutoffs
and methods. Pre, before dose 1; post IV, 3 weeks after the
fourth dose; Post IV CT, patients who had received platinum-
based chemotherapy before study enrollment; Post IV no CT,
patients who had not received prior chemotherapy.
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CD4-positive responses appeared to be dose dependent
and was observed to be highest in cohort 3. In a parallel
study in patients with metastatic melanoma, the PRAME
immunotherapeutic also induced humoral immune re-
sponses in all patients and a CD4-positive response in
most patients.40
In our study, signs of CD8-positive T-cell immuno-
genicity were detectable in a few patients and protocol-
deﬁned CD8-positive T cells responses were absent. By
contrast, PRAME-speciﬁc CD8-positive T-cell immuno-
genicity was reported ex vivo in patients with leuke-
mia.45 Immunization of patients with acute myeloid
leukemia with dendritic cells generated from autologous
leukemic blasts induced speciﬁc CD8-positive T-cell re-
sponses (using enzyme-linked immunospot assay)
against PRAME.46
CD8-positive cells are considered the main effector
cells involved in direct killing of malignant cells, and
adoptive cell transfer of tumor-inﬁltrating CD8-positive
cells to patients with melanoma can mediate tumor
regression.47 However, recent evidence points to an
important and previously underestimated role of CD4-
positive cells in facilitating CD8-positive cell activity
and in direct killing of tumor cells.48,49 In addition to
inﬂuencing development of CD8-positive cell memory,
the anticancer activities of CD4-positive cells include
directly and indirectly activating cytotoxic killing and
production of cytokines that impact tumor cell–aging
mechanisms.48 Adoptive transfer of CD4-positive T cells
along with CD8-positive T cells in mice appeared to
improve and prolong therapeutic efﬁcacy.50 Thus, strongCD4-positive responses induced by the PRAME immu-
notherapeutic may point to the presence of enhanced
antitumor activity. Furthermore, recent results of large
trials evaluating immune checkpoint inhibitors and
another cancer immunotherapeutic suggest that the in-
duction of tumor-speciﬁc immune responses may be
insufﬁcient for improving clinical outcomes in
the absence of releasing the immune blockade
(Vansteenkiste et al., in press).4–16,23,24,37
As observed in the parallel study in metastatic mel-
anoma, no patient had a CD8-positive T-cell response
according to the predeﬁned response criteria, although
signs of T-cell immunogenicity were detected. Very low
levels of antigen-speciﬁc CD8-positive cells induced by
vaccination with a tumor antigen have been reported
previously.51 Furthermore, active immunotherapy with
recombinant proteins has not been associated with
substantial CD8-positive T-cell responses.52 Thus,
although the sensitivity and speciﬁcity of T-cell assays
will directly affect detection rates, it is likely that the
weak T-cell responses we observed are due to low in-
duction of antigen-speciﬁc CD8-positive responses by
the recombinant protein. It is worth noting that at the
time of the study, the role of CD8-positive T cells and
checkpoint inhibition in anticancer responses was less
well recognized than today. Our data raise the question
whether a combination of the PRAME immunothera-
peutic and a checkpoint inhibitor would have enhanced
effects on cytotoxic T cells.
CMI responses should be included as end points for
future studies of cancer immunotherapeutics.
An exploratory analysis showed no negative impact
of prior chemotherapy on humoral or CMI responses.
In conclusion, consistent with a parallel phase I dose
escalation study in patients with metastatic melanoma,
in this study conducted in patients with resected NSCLC,
the PRAME immunotherapeutic dose of 500 mg was
immunogenic in most patients with NSCLC with a clini-
cally acceptable safety proﬁle. This dose was selected for
further evaluation in a randomized phase II study
(NCT01853878). However, the study was stopped early
when results of a large phase III study of another similar
immunotherapeutic showed no beneﬁt of treatment
compared with placebo in patients with NSCLC.37
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